Compare PTCT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | TMDX |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.6B |
| IPO Year | 2006 | 2019 |
| Metric | PTCT | TMDX |
|---|---|---|
| Price | $62.76 | $129.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | $79.41 | ★ $152.33 |
| AVG Volume (30 Days) | ★ 1.0M | 757.9K |
| Earning Date | 05-12-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 264.48 | ★ 382.18 |
| EPS | ★ 7.78 | 4.87 |
| Revenue | $264,734,000.00 | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.12 |
| Revenue Next Year | $21.65 | $18.69 |
| P/E Ratio | ★ $8.14 | $28.89 |
| Revenue Growth | 36.19 | ★ 37.13 |
| 52 Week Low | $35.95 | $62.42 |
| 52 Week High | $87.50 | $156.00 |
| Indicator | PTCT | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 21.26 | 42.98 |
| Support Level | $57.74 | $124.45 |
| Resistance Level | $63.19 | $142.44 |
| Average True Range (ATR) | 2.77 | 8.65 |
| MACD | -0.57 | 0.04 |
| Stochastic Oscillator | 8.82 | 8.58 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.